Anti-Cleaved-Notch 2 (D1733) Antibody |产品详情|进口试剂采购网

您好，欢迎来到拜力生物网站！请登录注册

我的订单 | 联系我们 | 在线客服QQ：3012681483 | 客服电话：400-968-7988 | 工作时间：08:30-17:30

主营产品： ELISA试剂盒、抗体、补体血清、兔补体、干扰素、小鼠测温仪、进口试剂、Quidel代理、Swant代理、PBL Assay Science代理

网站首页产品中心代理品牌新闻资讯资源中心关于我们

所在位置：首页 > 产品中心 > Antibodies > Antibodies产品

订购信息

上海拜力生物科技公司

Tel:400-968-7988 021-33779008

Anti-Cleaved-Notch 2 (D1733) Antibody

品牌：Antibodies

货号：

规格：50µl

货期：

应用：

咨询客服

立即购买加入购物车

Anti-Cleaved-Notch 2 (D1733) Antibody

商品详情参考文献相关资料

Overview

Name:	Anti-Cleaved-Notch 2 (D1733) Antibody See all Cleaved-Notch 2 primary antibodies
Description:	Rabbit polyclonal antibody to Cleaved-Notch 2 (D1733)
Specificity:	Cleaved-Notch 2 (D1733) pAb detects endogenous levels of Notch 2 protein intracellular domain.
Applications:	WB, IHC
Reactivity:	Human, Mouse, Rat
Immunogen:	Synthetic peptide, corresponding to amino acids 1700-1733 of Human Notch 2.
Host:	Rabbit
Clonality:	Polyclonal
Conjugate:	Unconjugated
Molecular Weight:	~ 85, 110 kDa
Purity:	The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE).
Product Form:	1mg/ml in PBS?with?0.1%?Sodium?Azide,?50%?Glycerol.

Target

Function:	Functions as a receptor for membrane-bound ligands Jagged1, Jagged2 and Delta1 to regulate cell-fate determination. Upon ligand activation through the released notch intracellular domain (NICD) it forms a transcriptional activator complex with RBPJ/RBPSUH and activates genes of the enhancer of split locus. Affects the implementation of differentiation, proliferation and apoptotic programs (By similarity). Involved in bone remodeling and homeostasis. In collaboration with RELA/p65 enhances NFATc1 promoter activity and positively regulates RANKL-induced osteoclast differentiation. Positively regulates self-renewal of liver cancer cells (PubMed:25985737).
Tissue Specificity:	Expressed in the brain, heart, kidney, lung, skeletal muscle and liver. Ubiquitously expressed in the embryo.
Involvement in Disease:	Alagille syndrome 2: A form of Alagille syndrome, an autosomal dominant multisystem disorder. It is clinically defined by hepatic bile duct paucity and cholestasis in association with cardiac, skeletal, and ophthalmologic manifestations. There are characteristic facial features and less frequent clinical involvement of the renal and vascular systems. Hajdu-Cheney syndrome: A rare skeletal disorder characterized by the association of facial anomalies, acro-osteolysis, general osteoporosis, insufficient ossification of the skull, and periodontal disease (premature loss of permanent teeth). Other features include cleft palate, congenital heart defects, polycystic kidneys, orthopedic problems and anomalies of the genitalia, intestines and eyes.
Sequence Similarities:	Belongs to the NOTCH family.
Post-Translational Modification:	Synthesized in the endoplasmic reticulum as an inactive form which is proteolytically cleaved by a furin-like convertase in the trans-Golgi network before it reaches the plasma membrane to yield an active, ligand-accessible form. Cleavage results in a C-terminal fragment N(TM) and a N-terminal fragment N(EC). Following ligand binding, it is cleaved by TNF-alpha converting enzyme (TACE) to yield a membrane-associated intermediate fragment called notch extracellular truncation (NEXT). This fragment is then cleaved by presenilin dependent gamma-secretase to release a notch-derived peptide containing the intracellular domain (NICD) from the membrane (By similarity).
Cellular Location:	Cell membrane.